# Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

> **NCT06316960** · PHASE2 · RECRUITING · sponsor: **Children's Hospital of Soochow University** · enrollment: 50 (estimated)

## Conditions studied

- AML, Childhood
- Relapse/Recurrence
- Refractory AML
- Core Binding Factor Acute Myeloid Leukemia
- C-KIT Mutation

## Interventions

- **DRUG:** Avapritinib
- **DRUG:** Azacitidine Injection
- **DRUG:** Decitabine Injection
- **DRUG:** Idarubicin Hydrochloride
- **DRUG:** Cytarabine
- **DRUG:** Granulocyte Colony-Stimulating Factor

## Key facts

- **NCT ID:** NCT06316960
- **Lead sponsor:** Children's Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-01
- **Primary completion:** 2026-03
- **Final completion:** 2027-03
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06316960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06316960, "Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06316960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*